Fertility Preservation During Cancer Treatment: A Comprehensive Guide

Cancer therapies—chemotherapy, radiation, surgery, hormone treatment, and stem‑cell transplantation—can alter hormone levels or damage reproductive organs. Options such as sperm banking, egg freezing, or embryo cryopreservation give many patients hope of future biological parenthood.

Improved survival rates mean more people are confronting the long‑term side effects of treatment, including the risk of infertility. Below we examine how the main cancer modalities impact male and female fertility and what evidence‑based preservation strategies are available.

How cancer treatment affects female fertility

Chemotherapy can harm the ovaries and disrupt hormonal balance, sometimes leading to premature ovarian failure. A 2023 review identified alkylating agents and topoisomerase inhibitors as especially damaging, reducing ovarian follicle counts and raising infertility risk. Antimetabolites such as methotrexate may cause temporary follicle loss, while taxanes can lower anti‑Müllerian hormone levels—a marker of ovarian reserve.

How cancer treatment affects male fertility

Chemotherapy targets rapidly dividing cells, including spermatogonia, the precursors of sperm. Early in treatment, spermatocyte numbers drop, followed by a gradual decline in overall sperm output. The result can be a reduced sperm count, altered DNA integrity, or complete azoospermia. Hormonal shifts induced by chemotherapy may further compromise sperm production.

Radiation therapy and female fertility

Ionizing radiation can deplete ovarian follicles, precipitating early menopause and uterine changes that affect implantation and increase risks of preterm birth or low birth weight. Radiation to the pelvis may also impair cervical function, and cranial irradiation can disrupt the hypothalamic‑pituitary axis, leading to irregular or absent menstrual cycles.

Radiation therapy and male fertility

Testicular exposure to radiation damages sperm‑producing tissue. High doses often cause permanent infertility; lower doses may result in a temporary dip that can recover over months to years, depending on age, dose, and field size.

Hormone (endocrine) therapy and female fertility

Endocrine therapies for hormone‑sensitive cancers (e.g., breast cancer) block or modify estrogen signaling, which can halt ovulation and lead to amenorrhea, reducing the chance of conception while the medication is taken.

Hormone therapy and male fertility

Androgen‑deprivation therapy for prostate cancer lowers testosterone, a key driver of sperm production. Men may experience a marked drop in sperm count and may also develop erectile dysfunction, both of which affect fertility.

Surgical impacts on female fertility

Procedures that remove ovaries, uterus, fallopian tubes, or cervix directly eliminate reproductive capacity. Even organ‑sparing surgeries can cause scarring or vascular injury that compromises fertility.

Surgical impacts on male fertility

Testes, seminal vesicles, or portions of the penis may be removed in cancer surgery. Scar tissue, nerve damage, or disrupted blood flow can impair ejaculation or sperm production.

Stem‑cell transplantation (SCT)

SCT often involves high‑dose chemotherapy and sometimes total‑body irradiation, both of which are highly gonadotoxic. Women may face ovarian failure and menstrual disturbances; men may experience lasting spermatogenic loss.

Fertility‑preservation options for women

• Embryo or oocyte cryopreservation: Ovarian stimulation, egg retrieval, fertilization (for embryos), and freezing.
• In vitro maturation (IVM) and ovarian tissue freezing: Immature oocytes are matured in the lab; ovarian cortex can be cryopreserved for later re‑implantation.
• Fertility‑sparing surgery: Techniques such as radical trachelectomy retain uterine function while removing cancerous tissue.
• Ovarian tissue re‑implantation: Thawed tissue is grafted back after remission, potentially restoring hormone production and fertility.
• Pharmacologic ovarian protection: Gonadotropin‑releasing hormone analogues may shield the ovaries during chemotherapy.
• Experimental stem‑cell approaches: Research is exploring ovarian‑derived stem cells to regenerate damaged tissue.

Fertility‑preservation options for men

• Sperm cryopreservation: Semen is collected, frozen, and stored for future use in IVF or IUI.
• Testicular shielding during radiation: Lead shields or gonadal cups reduce scatter dose.

Coping with potential infertility

• Discuss preservation options early with your oncology and fertility teams.
• Consider counseling or support groups to address emotional stress.
• Stay informed about emerging technologies and clinical trials.
• Consult a reproductive specialist for personalized guidance.
• Explore adoption or surrogacy if biological options are limited.
• Maintain hope—many patients regain fertility after treatment.

Pre‑pubescent children may benefit from experimental tissue‑cryopreservation, though ethical considerations and uncertain outcomes warrant careful discussion.

Some treatments cause only temporary infertility; sperm production or ovarian function often recovers within months to a few years after therapy ends.

Cost‑wise, sperm banking is generally the most affordable (a few hundred dollars for collection and annual storage). Egg freezing typically runs several thousand dollars, but many clinics offer financing plans or assistance programs.

Modern fertility‑preservation techniques empower patients to envision family building after cancer treatment, turning a daunting side effect into a manageable, hopeful possibility.